Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G/A for Ovid Therapeutics Inc. Common Stock (OVID).
- Disclosed ownership: 1.9%.
- Date of event: 30 Jun 2025.
BlackRock, Inc. - 30 Jun 2025 SCHEDULE 13G/A Report for Ovid Therapeutics Inc. Common Stock (OVID)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Security
- Ovid Therapeutics Inc. Common Stock
- Symbol
- OVID
- Shares outstanding
- 72,053,158 shares
- Disclosed Ownership
- 1,369,010 shares
- Ownership
- 1.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Jul 2025, 20:12:42 UTC
- Date of event
- 30 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 1.9% ownership in Ovid Therapeutics Inc. Common Stock (OVID) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Jul 2025, 20:12.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 1.9% | 1,369,010 | 1,359,560 | 0 | Spencer Fleming | Managing Director |